This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
CTI BioPharma Corporation
Drug Names(s): BB-76163, CHR2797, CHR-2797
Description: CHR-2797 is a small molecule aminopeptidase inhibitor that has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.
CHR-2797 leads to signs of amino acid deprivation in sensitive cells by targeting intracellular members of the M1/17 family of aminopeptidases, such as puromycin-sensitive aminopeptidase (PuSA), leucine aminopeptidase (LAP), and leukotriene A4 hydrolase (LTA4 hydrolase). Its cytoreductive properties in AML may occur through aminopeptidase N.
Vernalis and Serono
In October 2000, Vernalis and Serono S.A. signed a two-year agreement to jointly research, develop and commercialise metalloenzyme inhibitors for the treatment of various inflammatory diseases. Under the terms of the agreement, Vernalis received from Serono an up-front payment of $5 million. The agreement with Serono covered BB-76163 and research activities. The pre-clinical research of BB-76163 was terminated in 2001.
In October 2002, the term of the research agreement was extended, terminating in October 2003, subject to the exercise by Serono of its option of develop and commercialise certain compounds from the research agreement on terms whereby Vernalis receive milestone and royalty payments.
Vernalis and Chroma
On November 24, 2003, Vernalis entered into an agreement with Chroma Therapeutics Limited (Chroma) under which Vernalis granted Chroma an exclusive license covering BB-76163 for use in cancer. Vernalis was paid a...See full deal structure in Biomedtracker
Partners: Vernalis Group plc
Additional information available to subscribers only: